Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Moderna shares extend gains as hantavirus vaccine work draws attention
07:42am, Monday, 11'th May 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares continued to extend recent gains on Monday as investors welcomed reports that the company is researching a...
Moderna Stock Jumps. U.S. Passenger on Hantavirus Cruise Ship Tests Positive.
05:29am, Monday, 11'th May 2026
The U.S. health department said one passenger on a repatriation flight has tested mildly positive for the virus, while another is currently experiencing mild symptoms.
How Hantavirus Made Moderna a Must-Own Stock Again
02:44pm, Friday, 08'th May 2026
The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.
Moderna Stock Rises On Positive Phase 3 Flu Data: What Investors Need To Know
09:31am, Friday, 08'th May 2026
Moderna Inc (NASDAQ:MRNA) shares are trading higher Friday morning as traders react to peer reviewed Phase 3 flu-vaccine data. Here's what investors need to know.
Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to begin in 2026 CAMBRIDGE, MA / ACCESS Newswire / May 6, 2026 / Moderna, Inc. (NASDAQ:
Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial
05:01pm, Wednesday, 06'th May 2026
Moderna's mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of more than 40,000 adults aged 50 and older, researchers reported on Wednesd
Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era
10:09am, Monday, 04'th May 2026
Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking.
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges
02:00am, Saturday, 02'nd May 2026
Revenue: $400 million for Q1 2026, a $300 million increase year-over-year.Net Loss: $1.3 billion on a GAAP basis; $0.5 billion excluding litigation settlement.
Moderna, Inc. (MRNA) Q1 2026 Earnings Call Transcript
05:51pm, Friday, 01'st May 2026
Moderna, Inc. (MRNA) Q1 2026 Earnings Call Transcript
Stock Market Today, May 1: Tech Stocks Soar on Apple Earnings
12:52pm, Friday, 01'st May 2026
Today, May 1, 2026, Apple's earnings beat extended April's record-setting run for major U.S. benchmarks and spotlighted tech's dominance.
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales
12:35pm, Friday, 01'st May 2026
MRNA narrows Q1 loss and beats revenue estimates as international vaccine sales surge, lifting shares despite hefty litigation charges.
Revenue was $389 million. The analyst estimate was $130.62 million.GAAP EPS was -$3.40. The analyst estimate was -$2.17.Net loss was $(1.343) billion, includin
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings
11:55am, Friday, 01'st May 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported first quarter 2026 revenue that came in well above Wall Street expectations, but posted a wider-than-expected net loss and missed earnings estimates due i
Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook
10:58am, Friday, 01'st May 2026
Moderna (MRNA) delivered a strong 1Q26 revenue beat, driven by international COVID-19 vaccine sales, and reaffirmed 2026 guidance for up to 10% revenue growth. Cost discipline is improving, with R&D a
Moderna Sales Triple To $389 Million As Shares Rise 5.4%
10:55am, Friday, 01'st May 2026
Moderna (MRNA) reported first-quarter sales that came in ahead of expectations, giving investors a fresh signal that the vaccine maker may be finding growth out
